{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-080168","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.144995+00:00","generated_at":"2026-06-13T09:25:13.590399+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Leap Therapeutics starts randomized Part B of DKN-01 Phase 2 CRC study after positive Part A","bullets":["Initiated 130-patient randomized controlled Part B of DeFianCe study of DKN-01 in second-line advanced colorectal cancer.","Part A enrolled 33 aggressive CRC patients and exceeded 20% overall response rate, triggering Part B.","Primary endpoint of Part B is progression-free survival; enrollment expected ~12 months, data late 2024.","Regained Nasdaq compliance with minimum bid price rule after 11 consecutive days above $1.00 (July 6, 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-080168","json":"https://secwatch.observer/filing/0001104659-23-080168.json","markdown":"https://secwatch.observer/filing/0001104659-23-080168.md","text":"https://secwatch.observer/filing/0001104659-23-080168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923080168/0001104659-23-080168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923080168/tm2321081d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:25:13.590399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}